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Abstract
Background—Osteosarcoma is a rare bone tumor that is the most frequently diagnosed among 
children and adolescents, although this cancer affects people of all ages. This study aims to 
augment the current literature by examining the incidence of osteosarcoma by its subsites on a 
national level.
Methods—Data from central cancer registries in the National Program of Cancer Registries 
(NPCR) and Surveillance, Epidemiology, and End Results (SEER) programs for diagnosis years 
1999-2008 and covering 90.1% of the US population were analyzed. Analyses included cases of 
malignant primary osteosarcomas, which were further segmented by topography, appendicular 
(C40) and axial (C41), to assess differences between these sites. Descriptive statistics, including 
estimated age-adjusted incidence rates standardized to the 2000 US standard population, were 
calculated using SEER*Stat 7.0.5 software.
Results—Approximately 7,104 cases of malignant primary osteosarcomas were identified during 
1999-2008, of which 5,379 were appendicular and 1,725 were axial The incidence of malignant 
primary osteosarcomas differed by age, gender, race, ethnicity, region, grade, and stage. These 
differences in incidence persisted when malignant primary osteosarcomas were categorized by 
topography codes.
Conclusions—These analyses provide a better understanding of the incidence of malignant 
osteosarcoma which cover 90.1 % of the US population from 1999-2008. This study provides a 
more detailed understanding of age, gender, race, and ethnicity by primary site for malignant 
osteosarcoma incidence on a national level in the United States. More importantly, differences 
between appendicular and axial sites were observed overall by selected demographic 
characteristics, in particular regional variations.
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Osteosarcoma is a rare bone tumor that is most frequently diagnosed among children and 
adolescents, although this cancer affects people of all ages.1-5 While the incidence of 
primary osteosarcoma peaks during adolescence, a second incidence peak occurs among 
individuals over age 60, most commonly in the seventh or eighth decades of life,3,5,6 Among 
15-29 year olds, most osteosarcomas occurred in the metaphyses of long bones and 
particularly the distal femur, proximal humerus, and the proximal tibia.1 Among older 
adults, osteosarcomas are more likely to occur in the axial skeleton locations and in areas 
that have been previously irradiated or have underlying bone abnormalities.7 Males are 
affected more frequently than females except during the first decade of life.6
Currently, there is a paucity of information on osteosarcoma in the US population.3,5 In 
order to understand the burden of osteosarcoma, this study will analyze the incidence of 
osteosarcoma by topography (primary site) and demographic characteristics, including age 
groups, race, ethnicity, and gender.
Materials and Methods
Microscopically confirmed incident cases of invasive primary osteosarcoma were identified 
from population-based cancer registries that participated in the Centers for Disease Control 
and Prevention’s (CDC) National Program of Cancer Registries (NPCR) or the National 
Cancer Institutes’ (NCI) Surveillance, Epidemiology, and End Results (SEER) Program. 
NPCR supports central cancer registries (CCRs) in 45 states, the District of Columbia, 
Puerto Rico, and US Pacific Island jurisdictions, which cover approximately 96% of the US 
population.8 Together, NPCR and SEER collect cancer incidence data for the entire US 
population.8,9 Cancer incidence data for this study included those from the NPCR-Cancer 
Surveillance System (NPCR-CSS) November 2010 submission and the November 2010 
SEER submission. The analyses focused on microscopically confirmed incident malignant 
primary osteosarcoma cases diagnosed between 1999-2008 from CCRs in 44 states that met 
case ascertainment and quality criteria for all 10 years.9 These data cover approximately 
90.1% of the US population during these 10 years. Data from 6 states and the District of 
Columbia (7 CCRs) were excluded because case ascertainment and quality criteria standards 
were not met for the entire time period.
Tumors were included in the study if they were the only primary tumor or the first of 2 or 
more independent primary tumors for the patient. All malignant primary osteosarcomas 
were classified according to the International Classification of Diseases for Oncology (ICD-
O-3).10 Since the International Classification of Childhood Cancers (ICCC) is similar to 
ICD-O-3 for osteosarcomas, it was decided to use the classification schemes from ICD-O-3 
only. We included all malignant primary osteosarcomas (primary site code C40.0-40.9 and 
C41.0-41.9 and histology codes 9180/3-9187/3, 9192/3-9195/3, 9200/3) in these analyses. 
Table 1 shows the topography codes (primary site) used to define appendicular and axial 
sites for malignant primary osteosarcomas.11 Osteosarcoma histologic groupings were coded 
according to the version of the International Classification of Diseases for Oncology (ICD-
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O) used at the time of diagnosis.10, 12 The osteosarcoma cases diagnosed from 1999 to 2000 
used the ICD-O second edition (ICD-O-2), and those from 2001 to 2008 used the ICD-O 
third edition (ICD-O-3); data from the 1999-2000 diagnosis years were converted to the 
ICD-O-3 codes. Table 2 shows the histologic codes used to define malignant primary 
osteosarcomas in these analyses.
Cancer stage was assigned SEER summary stage 1977 (SS77) for cases diagnosed before 
2001, SEER summary stage 2000 (SS2000) for cases diagnosed during 2001-2003, and 
derived summary stage using the collaborative stage algorithm for cases diagnosed in 2004 
or later.13 These data were then aggregated to obtain an overall frequency count for stage. 
Stage was categorized as in situ, localized, regional, distant, or unstaged. Grade was 
categorized as I (well differentiated), II (moderately differentiated), III (poorly 
differentiated), IV (undifferentiated/anaplastic), or unknown.
Race was categorized as white, black, American Indian/Alaska Native (AI/AN), Asian/
Pacific Islander (API), or other/unknown race. To increase the accuracy of the AI/AN 
designation, linkages between the CCRs and the Indian Health Service (IHS) database were 
completed before data submission to NPCR and SEER. Ethnicity was categorized as 
Hispanic or non-Hispanic based on the North American Association of Central Cancer 
Registries’ (NAACCR) Hispanic/Latino Identification Algorithm (NHIA) which employs a 
combination of variables to assign Hispanic/Latino classification to cancer cases.14 Cases 
that are not classified as Hispanic by NHIA are classified as non-Hispanic which leaves no 
cases with an unknown Hispanic status.15 Nearly all NPCR and SEER registries assign 
Hispanic ethnicity through the standardized use of the NHIA.15 Race and ethnicity are not 
mutually exclusive.
Frequencies by demographic and tumor characteristics for all malignant primary 
osteosarcomas were calculated. Age-adjusted incidence rates with 95% confidence intervals 
(95% CI) for all malignant primary osteosarcomas were calculated overall, and by gender, 
race, ethnicity, US Census regions (Northeast, Midwest, South, and West), grade, and stage. 
Rates were expressed per 1,000,000 persons and age-adjusted using the US 2000 population 
standard (19 age groups—Census P25-1130). Counts and rates based on fewer than 16 cases 
were not presented to ensure rate stability and confidentiality. All data analyses for this 
study were performed using SEER*Stat version 7.0.5.16
Results
Table 3 shows demographic and tumor characteristics for malignant osteosarcomas by 
topography (primary site) for cases diagnosed during the 1999-2008 period. Of the reported 
7,104 malignant osteosarcoma incident cases diagnosed from 1999 to 2008,5,379 (76%) 
were appendicular and 1,725 (24%) were axial. The age-adjusted incidence rate for 
appendicular malignant osteosarcomas (2.06 per 1,000,000) was higher than axial (0.65 per 
1,000,000).
Rates for appendicular malignant osteosarcoma peaked for 2 age groups: 10-19 years and 
80+ years. However, for axial malignant osteosarcomas, incidence rates were much lower 
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and the peaks varied more with peaks at 10-19 years of age, at 40-49 years of age, and 80+ 
years. The age-specific incidence rate for appendicular malignant osteosarcomas was lowest 
among adults aged 50-59 years (0.78 per 1,000,000) and was highest among adolescents 
aged 10-19 years (7.08 per 1,000,000), However, the age-specific incidence rate for axial 
malignant osteosarcoma was lowest among children aged less than 10 years (0.11 per 
1,000,000) and highest among adults aged 80+ years (1.17 per 1,000,000).
Moreover, differences in malignant osteosarcomas by gender were also observed. Among 
axial malignant osteosarcoma, the frequency was distributed almost equally by gender, 
whereas among appendicular malignant osteosarcoma cases, the distribution was slightly 
higher among males (57%) compared with females (43%). In addition, the appendicular 
malignant osteosarcoma age-adjusted rates among males (2.32 per 1,000,000) were higher 
than those observed among females (1.79 per 1,000,000) but no difference was seen in axial 
malignant osteosarcomas age-adjusted incidence rates by gender.
Among appendicular and axial cases, the predominant race group was whites 
(approximately 80%) followed by blacks (16%). Age-adjusted rates for appendicular and 
axial malignant osteosarcomas were higher among blacks than whites, American Indian/
Alaska Natives, or Asian/Pacific Islanders. With respect to ethnicity, non-Hispanics 
accounted for approximately 81% of the reported cases among appendicular malignant 
osteosarcomas but almost 90% among axial malignant osteosarcomas. Moreover, Hispanics 
age-adjusted incidence for appendicular malignant osteosarcomas was higher than non-
Hispanics.
Among appendicular and axial cases the geographic region with the largest proportion of 
cases (approximately 30%) occurred in the South with about 20%-26% of the remaining 
cases distributed in each of the remaining 3 regions (Northeast, Midwest, and West). 
Appendicular and axial rates among the 4 geographic regions were not different.
More than one third of appendicular cases were grade IV (37%), followed by unknown 
grade (29%) and grade III (25%). For the axial site, unknown grade contributed 33% of 
cases followed by grade III (27%), and grade IV (25%). The age-adjusted incidence rates 
were higher among appendicular cases for grade IV (0.77 per 1,000,000) when compared 
with other grades, whereas unknown cases accounted for the highest incidence rate (0.22 per 
1,000,000) for axial cases.
For appendicular osteosarcomas, the highest proportion of cases were localized (41%). Most 
axial cases were diagnosed with regional stage (37%). The age-adjusted rates were higher 
among appendicular cases for localized stage (0.84 per 1,000,000), whereas regional stage 
(0.24 per 1,000,000) was higher for axial cases. Total malignant osteosarcomas had the 
highest age-adjusted incidence rates in localized stage (1.01 per 1,000,000) compared with 
other stages at diagnosis. Appendicular osteosarcomas had the highest age-adjusted 
incidence rates in the localized stage (0.84 per 1,000,000) compared with regional stage 
(0.24 per 1,000,000) among axial osteosarcomas.
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Figure 1 presents the incidence of malignant osteosarcomas by primary site and age (5-year 
intervals). Incidence rates peaked among 2 age groups: 15-19 year-olds (adolescence) and 
80-84 year-olds (elderly).
Discussion
These analyses provide detailed information on the descriptive epidemiology of malignant 
osteosarcomas complementing 2 recent studies published by Mirabello et al which reported 
the incidence and survival rates of osteosarcoma from 1973 to 2004 using SEER data in the 
United States, as well as the international osteosarcoma incidence patterns among children 
and adolescents, and middle-aged and elderly persons.3,17 The current study covers more 
than 90% of the US population. Together, these studies provide a detailed assessment of the 
burden of primary osteosarcomas.
Our results confirms previous findings of a bimodal frequency distribution for osteosarcoma 
incidence by age with the first peak occurring during adolescence and the second peak 
among adults over 60 years of age in the United States.3,6,17 Anfinsen et al reported a 
bimodal distribution with the highest incidence rate occurring in the second decade of life, 
with a decline between 30 and 50 years of age, followed by a second peak among those aged 
75-79.6 Mirabello et al study reported an observed bimodal osteosarcoma incidence pattern.3
Differences in incidence rates by gender were found overall and by primary site. Among 
axial osteosarcoma, the frequency was distributed almost equally by gender, whereas among 
total and appendicular malignant osteosarcoma cases, the distribution was higher among 
males compared with females. An international study by Mirabello et al on osteosarcomas 
also reported that osteosarcoma was more common in males than females in most 
countries.17 Bleyer et al reported a higher incidence of malignant osteosarcomas among 
males than females among the adolescent and young adult population in the United States.1 
Anfinsen et al reported that male predominance was generally apparent at the older ages and 
at ages less than 30 years, in contrast to modest and inconsistent sex differences among the 
middle age groups in the United States.6 A possible explanation for these observed sex 
differences in osteosarcoma incidence rates may be attributed to hormonal differences 
between genders. The effects of these sex steroids on osteoblasts have been well-
documented both in vivo and in vitro.18-21 However, there is limited research on the possible 
effects of sex steroids in human osteosarcomas. Study findings by Dohi et al, however, 
suggest that inhibitors of sex steroid actions could be a potential treatment for osteosarcoma 
in the future.22 A study in England by Arora et al reported that a key factor in osteosarcoma 
development may be related to pubertal bone growth due to observed variations in incidence 
patterns by age and site.23 However, Arora et al stated that although pubertal growth may be 
a biological plausibility, further research may be required to establish this link.23
Differences were observed in our study by race and ethnicity separately. Among 
appendicular and axial cases, approximately 80% were found among whites followed by 
blacks (16%). In contrast, age-adjusted incidence rates for appendicular and axial malignant 
osteosarcomas were higher among blacks compared with other racial groups. Mirabello et al 
have reported similar results using SEER data.3 With respect to ethnicity, non-Hispanics 
Duong and Richardson Page 5









accounted for approximately 81% of the reported cases among total and appendicular 
malignant osteosarcomas but almost 90% among axial malignant osteosarcomas. Moreover, 
Hispanics had a higher age-adjusted incidence rate than non-Hispanics for appendicular but 
a similar rate for axial cases. Bleyer et al reported that Hispanics had the highest incidence 
of osteosarcoma among those aged 15-29 in the United States.1
There were no differences observed in the regional data within subsites we analyzed. The 
Northeast, Midwest, South, and West all had similar incidence rates within their respective 
subsites. However, differences were observed between subsites. The incidence of 
osteosarcoma in the appendicular sites tended to be higher (ranged between 2.03-2.10 per 
1,000,000) in these regions than axial (ranged between 0.57-0.70 per 1,000,000), An 
international study by Mirabello et al reported minimum variability in osteosarcoma 
incidence rates between countries in individuals ≤24 years. The country data were from the 
Cancer Incidence in Five Continents from the International Agency for Cancer Research 
(IARC) database. Overall, they reported that worldwide osteosarcoma incidence rates varied 
mostly among the elderly with little geographic variation among the younger age group.17
Our findings should be considered in light of several limitations. In registry data, there is a 
possibility of misclassification or miscoding especially with rare tumors. In addition, data 
were not available for 7 CCR in the 1999-2008 analytic dataset because they did not meet 
case ascertainment and quality criteria.9 The exclusion of these CCRs may have influenced 
the observed osteosarcoma incidence rates. Although we used data that had been linked to 
the IHS database to increase the accuracy of the AI/AN designation, race misclassification 
of these cases and other cases may still remain. However, a study by Clegg et al indicated 
that this may not be a strong limitation for cancer incidence any longer.24 Finally, even 
though the NHIA algorithm was used to assign ethnicity for Hispanics, ethnicity 
misclassification may also occur,24 Despite these limitations, our study is one of the first to 
report on malignant osteosarcoma incidence by primary site which covers over 90% of the 
US population. In addition, we were among the first studies to categorize osteosarcoma by 
appendicular and axial sites. Differences observed in these analyses between these sites 
provide further insight into the incidence of these tumors in these sites.
These analyses provide a better understanding of the incidence of malignant osteosarcoma 
using population-based data covering approximately 90.1% of the US population during 
1999-2008. In addition, these analyses provide a more detailed understanding of age, 
gender, race, and ethnicity by primary site for malignant osteosarcoma incidence on a 
national level in the United States. More importantly, differences between appendicular and 
axial sites were observed overall by selected demographic characteristics, in particular 
regional variations. These analyses by subsites are a strength of this study.
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Figure 1. Incidence of Primary Malignant Osteosarcomas, United States, 1999-2008
Rates are per million persons and age-adjusted to the 2000 US standard population (19 age 
groups—Census P25-1130). Rates pertain to 90.1% of the US population covered by 
eligible cancer registries. Data from 7 central cancer registries are not included.
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Table 1
Topography Codes* Used to Define Malignant Primary Osteosarcomas† by Appendicular 
and Axial Sites, United States, 1999-2008





 Long bones of upper limb, scapula, and
 associated joints
C40.0
 Short bones of upper limb and associated joints C40.1
 Long bones of lower limb and associated joints C40.2
 Short bones of lower limb and associated joints C40.3
 Overlapping lesion of bones, joints, and
 articular cartilage of limbs
C40.8
 Bone of limb, NOS‡ C40.9
Axial C41
 Bones of skull and face and associated joints C41.0
 Mandible C41.1
 Vertebral column C41.2
 Rib, sternum, clavicle, and associated joints C41.3
 Pelvic bones, sacrum, coccyx, and
 associated joints
C41.4
 Overlapping lesion of bones, joints, and
 articular cartilage
C41.8
 Bone, NOS C41.9
*
Topography codes from the American Joint Committee on Cancer (AJCC) Cancer Staging Handbook, 6th edition.
†
The analyses were limited to microscopically confirmed osteosarcomas.
‡NOS, not otherwise specified.









Duong and Richardson Page 11
Table 2
Histology Categories and ICD-O-3,* Codes Used to Define Malignant Primary 
Osteosarcomas† United States, 1999-2008
Histology Definitions for Primary





Osteosarcoma in Paget disease 9184/3
Small cell osteosarcoma 9185/3
Central osteosarcoma 9186/3
Intraosseous well differentiated osteosarcoma 9187/3
Paraosteal osteosarcoma 9192/3
Periosteal osteosarcoma 9193/3




ICD-O-3 indicates International Classification of Diseases for Oncology-3rd Edition
†
The analyses were limited to microscopically confirmed osteosarcomas.
‡NOS, not otherwise specified.
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Table 3
Description of Primary Osteosarcoma Incidence by Selected Characteristics, United 
States, 1999-2008
Appendicular (C40) Axial (C41) Total
Count* (%) Rate† (95% CI)‡ Count (%) Rate (95% CI) Count (%) Rate (95% CI)
Total 5, 379 (100.0%) 2.06 (2.01, 2.12) 1,725 (100.0%) 0.65 (0.62, 0.69) 7,104 (100.0%) 2.71 (2.65, 2.78)
Age at diagnosis, years
00-09 526 (9.8%) 1.48 (1.36, 1.61) 40 (2.3%) 0.11 (0.08, 0.15) 566 (8.0%) 1.59 (1.46, 1.73)
10-19 2,655 (49.4%) 7.08 (6.81, 7.35) 316 (18.3%) 0.84 (0.75, 0.94) 2,971 (41.8%) 7.92 (7.64, 8.21)
20-29 780 (14.5%) 2.16 (2.01, 2.31) 261 (15.1%) 0.72 (0.64, 0.82) 1,041 (14.7%) 2.88 (2.71, 3.06)
30-39 403 (7.5%) 1.07 (0.97, 1.18) 198 (11.5%) 0.53 (0.46, 0.61) 601 (8.5%) 1.60 (1.47, 1.73)
40-49 342 (6.4%) 0.86 (0.77, 0.95) 269 (15.6%) 0.68 (0.60, 0.76) 611 (8.6%) 1.54 (1.42, 1.66)
50-59 249 (4.6%) 0.78 (0.69, 0.89) 199 (11.5%) 0.63 (0.54, 0.72) 448 (6.3%) 1.41 (1.28, 1.55)
60-69 187 (3.5%) 0.93 (0.80, 1.07) 173 (10.0%) 0.87 (0.74, 1.01) 360 (5.1%) 1.80 (1.61, 1.99)
70-79 142 (2.6%) 0.97 (0.82, 1.15) 161 (9.3%) 1.10 (0.94, 1.29) 303 (4.3%) 2.08 (1.85, 2.32)
80+ 95 (1.8%) 1.03 (0.83, 1.26) 108 (6.3%) 1.17 (0.96, 1.41) 203 (2.9%) 2.20 (1.91, 2.53)
Gender
Male 3,057 (56.8%) 2.32 (2.24, 2.41) 885 (51.3%) 0.70 (0.65, 0.74) 3,942 (55.5%) 3.02 (2.93, 3.12)
Female 2,322 (43.2%) 1.79 (1.72, 1.87) 840 (48.7%) 0.62 (0.58, 0.66) 3,162 (44.5%) 2.41 (2.33, 2.50)
Race§
White 4,176 (77.6%) 1.99 (1.93, 2.05) 1,387 (80.4%) 0.64 (0.60, 0.67) 5,563 (78.3%) 2.63 (2.56, 2.70)
Black 856 (15.9%) 2.42 (2.26, 2.59) 252 (14.6%) 0.81 (0.71, 0.92) 1,108 (15.6%) 3.23 (3.03, 3.43)
AI/AN # 1.34 (0.97, 1.83) # # 54 (0.8%) 1.87 (1.36, 2.51)
API 220 (4.1%) 1.75 (1.52, 2.00) 53 (3.1%) 0.45 (0.33, 0.59) 273 (3.8%) 2.19 (1.94, 2.48)
Ethnicity∥
Hispanic 1,037 (19.3%) 2.37 (2.22, 2.54). 222 (12.9%) 0.64 (0.55, 0.74) 1,259 (17.7%) 3.01 (2.83, 3.20)
Non-Hispanic 4,342 (80.7%) 2.00 (1.94, 2.06) 1,503 (87.1%) 0.66 (0.62, 0.69) 5,845 (82.3%) 2.66 (2.59, 2.73)
Region
Northeast 1,085 (20.2%) 2.06 (1.94, 2.19) 384 (22.3%) 0.70 (0.63, 0.77) 1,469 (20.7%) 2.76 (2.62, 2.90)
Midwest 1,310 (24.4%) 2.03 (1.92, 2.14) 417 (24.2%) 0.64 (0.58, 0.70) 1,727 (24.3%) 2.67 (2.54, 2.79)
South 1,571 (29.2%) 2.05 (1.95, 2.15) 545 (31.6%) 0.70 (0.65, 0.77) 2,116 (29.8%) 2.75 (2.64, 2.87)
West 1,413 (26.3%) 2.10 (1.99, 2.21) 379 (22.0%) 0.57 (0.52, 0.64) 1,792 (25.2%) 2.68 (2.55, 2.80)
Grade
I 220 (4.1%) 0.08 (0.07, 0.09) 95 (5.5%) 0.04 (0.03, 0.04) 315 (4.4%) 0.12 (0.11, 0.13)
II 261 (4.9%) 0.10 (0.09, 0.11) 153 (8.9%) 0.06 (0.05, 0.07) 414 (5.8%) 0.16 (0.14, 0.17)
III 1,350 (25.1%) 0.52 (0.49, 0.54) 462 (26.8%) 0.17 (0.16, 0.19) 1,812 (25.5%) 0.69 (0.66, 0.72)
IV 2,012 (37.4%) 0.77 (0.74, 0.81) 439 (25.4%) 0.17 (0.15, 0.18) 2,451 (34.5%) 0.94 (0.90, 0.98)
Unknown 1,536 (28.6%) 0.59 (0.56, 0.62) 576 (33.4%) 0.22 (0.20, 0.24) 2,112 (29.7%) 0.81 (0.78, 0.85)
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Appendicular (C40) Axial (C41) Total
Count* (%) Rate† (95% CI)‡ Count (%) Rate (95% CI) Count (%) Rate (95% CI)
Total 5, 379 (100.0%) 2.06 (2.01, 2.12) 1,725 (100.0%) 0.65 (0.62, 0.69) 7,104 (100.0%) 2.71 (2.65, 2.78)
Stage at diagnosis¶
In situ 0 (0.0%) 0.00 (0.00, 0.00) 0 (0.0%) 0.00 (0.00, 0.00) 0 (0.0%) 0.00 (0.00, 0.00)
Localized 2,181 (40.5%) 0.84 (0.80, 0.87) 472 (27.4%) 0.18 (0.16, 0.20) 2,653 (37.3%) 1.01 (0.98, 1.05)
Regional 1,837 (34.2%) 0.70 (0.67, 0.74) 630 (36.5%) 0.24 (0.22, 0.26) 2,467 (34.7%) 0.94 (0.91, 0.98)
Distant 938 (17.4%) 0.36 (0.34, 0.38) 393 (22.8%) 0.15 (0.13, 0.16) 1,331 (18.7%) 0.51 (0.48, 0.54)
Unstaged 423 (7.9%) 0.16 (0.15, 0.18) 230 (13.3%) 0.09 (0.08, 0.10) 653 (9.2%) 0.25 (0.23, 0.27)
AI/AN, American Indian/Alaska Native; API, Asian/Pacific Islander; SEER, National Cancer Institute’s Surveillance, Epidemiology, and End 
Results Program.
Percentages may not add to 100% because of rounding. The analyses were limited to microscopically confirmed osteosarcomas.
*Counts pertain to 90.1% of U.S population covered by eligible cancer registries. Data from 7 central cancer registries are not included.
†
Rates are per 1,000,000 persons and age-adjusted to the 2000 US standard population (19 age groups - Census P25-1130) except age-specific rates 
which were not age-adjusted.
‡95% CI indicates 95% confidence interval and were calculated using the Tiwari modification.
§Other unspecified/unknown race accounted for 106 (1.5%) cases of primary osteosarcomas.
∥
Race and ethnicity are not mutually exclusive.
¶SEER summary stage 1977 was used for 1999–2000 cases, SEER summary stage 2000 was used for 2001–2003 cases, and derived summary 
stage 2000 [also known as collaborative stage) was used for 2004–2008 cases.
#Not presented due to count or rate instability or complementarity suppressed for confidentiality.
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